Sagimet Biosciences Inc.
sagimet.comWhat Do They Do?
Develops medicines that block a fat-producing enzyme for people with fatty liver disease, acne and certain cancers.
10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target…View ↗
In addition to MASH, we are evaluating our FASN inhibitors in acne, a disorder in which dysregulation of fatty acid metabolism also plays a…View ↗
Expand pipeline in indications beyond MASH and acne, where FASN plays a central role in disease pathogenesis. Based on our seminal work…View ↗
Who Are Their Customers?
Sagimet licensed denifanstat development, manufacturing and commercialization rights in Greater China to Ascletis; Gannex later assumed the license rights and obligations.
10-K for FY2025, filed Mar 11, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$14MView ↗
- ▲ +34% (Loss)
- vs −$10.4M in Q2 FY2025
-
Aug 13, 2026
FDA clears Phase 3 acne trial to proceed
The clearance covers denifanstat for moderate to severe acne in the United States.
Sources
8-K, filed Aug 13, 2026
On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the…View ↗
-
Aug 11, 2026
Prioritizes U.S. acne development and dermatology spending
Sagimet said it would advance denifanstat for U.S. acne and prioritize dermatology programs in capital allocation.
Sources
8-K, filed Aug 11, 2026
Strategic focus: In April 2026, Sagimet announced a strategic decision to advance denifanstat in moderate to severe acne for the U.S.…View ↗
Who Do They Compete With?
Competes with Altimmune, AstraZeneca, Boehringer Ingelheim, Zealand Pharma, Eli Lilly, Galmed Pharmaceuticals, Gilead Sciences, GSK, Inventiva, Madrigal, Merck &, Novo Nordisk, Pfizer, Roche Holdings, Terns Pharmaceuticals, Viking Therapeutics, and Zydus Therapeutics
10-K for FY2025, filed Mar 11, 2026The biopharmaceutical industry is characterized by intense competition and rapid innovation. Accordingly, our competitors may be able to…View ↗
Loading...
